Cargando…
Multi-kinase inhibition in ovarian cancer
Sorafenib (Nexavar) is a multi-kinase inhibitor that was developed as an inhibitor of RAF-1, in the ERK1/2 pathway, but which was subsequently shown to inhibit class III tyrosine kinase receptors.(1) More recently regorafenib (Stivarga) has been developed, which is a further fluorinated version of s...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938511/ https://www.ncbi.nlm.nih.gov/pubmed/24309512 http://dx.doi.org/10.4161/cbt.26708 |